2025 ASCO GI

CE / CME

CCO Independent Conference Highlights of the 2025 ASCO Gastrointestinal Cancers Symposium

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 1.50 Nursing contact hours

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: April 09, 2025

Expiration: October 08, 2025

Activity

Progress
1 2
Course Completed

References

  1. Kopetz S, Yoshino T, Van Cutsem E, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Net Med. 2025;31:901-908
  2. Encorafenib [prescribing information]. Boulder, CO: Array BioPharma; 2024.
  3. Cetuximab [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2024.
  4. Williams H. WW vs TME in patients with rectal cancer with a complete or near-complete response to TNT: pooled analysis of CAO/ARO/AIO-12 and OPRA trials. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium Annual Meeting; January 23-25, 2025. Abstract 21.​
  5. Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212-3222.
  6. Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546-2556.
  7. ‌Andre T. First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium Annual Meeting; January 23-25, 2025. Abstract LBA143.
  8. Fakih M. Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium Annual Meeting; January 23-25, 2025. Abstract 23.​
  9. Bullock AJ, Schlechter BL, Fakih MG, et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med. 2024;30:2558-2567.
  10. Hijioka S. A phase III study of combination therapy with everolimus plus lanreotide vs everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium Annual Meeting; January 23-25, 2025. Abstract 652.
  11. Singh S, Halperin D, Sten Myrehaug, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide vs high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807-2817.
  12. ‌Cabozantinib [prescribing information]. Alameda, CA: Exelixis, Inc; 2025.
  13. Chan JA, Geyer S, Zemla T, et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025;392:653-665.
  14. Sharma A. Adjuvant chemotherapy or chemo-radiation in gallbladder cancer: A phase III randomized controlled study (ACCELERATE trial). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium Annual Meeting; January 23-25, 2025. Abstract 519.​
  15. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663-673.
  16. Shroff RT, King G, Colby S, et al. SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel vs gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2025;43:536-544.